RETRACTED: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
SUMMARY Protein phosphatase 2A (PP2A) enzymes can suppress tumors, but they are often inactivated in human cancers overexpressing inhibitory proteins. Here, we identify a class of small-molecule iHAPs (improved heterocyclic activators of PP2A) that kill leukemia cells by allosterically assembling a specific heterotrimeric PP2A holoenzyme consisting of PPP2R1A (scaffold), PPP2R5E (B56ε, regulatory), and PPP2CA (catalytic) subunits. One compound, iHAP1, activates this complex but does not inhibit dopamine receptor D2, a mediator of neurologic toxicity induced by perphenazine and related neuroleptics. The PP2A complex activated by iHAP1 dephosphorylates the MYBL2 transcription factor on Ser241, causing irreversible arrest of leukemia and other cancer cells in prometaphase. In contrast, SMAPs, a separate class of compounds, activate PP2A holoenzymes containing a different regulatory subunit, do not dephosphorylate MYBL2, and arrest tumor cells in G1 phase. Our findings demonstrate that small molecules can serve as allosteric switches to activate distinct PP2A complexes with unique substrates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“Percent inhibition curves were drawn by PRISM software (GraphPad) and IC50 values for each compound were calculated by the median-effect method (Chou and Talalay, 1984).”
The DREAM complex: master coordinator of cell cycle-dependent gene expression
Sadasivam, S., & DeCaprio, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3556 · Cited by 524 · cited 4×
“MYBL2 has been shown to transactivate the expression of genes active in early M phase, including those that encode centriole components and other key mediators of spindle bipolarity (Heinrichs et al., 2013; Musa et al., 2017; Sadasivam and DeCaprio, 2013).”
BackgroundInfluentialAll roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312 · cited 6×
“Because the regulatory subunit of PP2A determines substrate specificity (Cundell et al., 2016; Hertz et al., 2016; Sangodkar et al., 2016), these findings indicate that the different PP2A complexes activated by iHAP1/PPZ and SMAP target different signal transduction pathways.”
InfluentialPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65093 · Cited by 220 · cited 8×
“Our discovery that perphenazine (PPZ) and related heterocyclic compounds can activate PP2A provided a new role for these compounds (Gutierrez et al., 2014), which are best known for their ability to bind and inhibit signaling by dopamine and related receptors in the cerebral cortex, accounting for their antipsychotic…”
BackgroundMethodInfluentialSelf-citationActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
A PP2A-B55 recognition signal controls substrate dephosphorylation kinetics during mitotic exit
Cundell, M. J., Hutter, L. H., Nunes Bastos, R., Poser, E., Holder, J., Mohammed, S., Novak, B., & Barr, F. A. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201606033 · Cited by 193
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
The structural basis for tight control of PP2A methylation and function by LCMT-1
Stanevich, V., Jiang, L., Satyshur, K. A., Li, Y., Jeffrey, P. D., Li, Z., Menden, P., Semmelhack, M. F., & Xing, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.030 · Cited by 142 · cited 7×
“Knockdown of PPME1, an Endogenous PP2A Inhibitor, Activates PP2A-B56ε Complexes and Causes Cell Cycle Arrest in Prometaphase PP2A can be activated through methylation of Lys309 in the catalytic subunit by leucine carboxyl methyltransferase 1 (LCMT1) (Stanevich et al., 2011).”
InfluentialMcClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
Hwang, J., Lee, J. A., & Pallas, D. C. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.739920 · Cited by 56 · cited 1×
“Thus, instead of relying on mutational inactivation of the PP2A subunit genes themselves, cancer cells generally evade PP2A-mediated tumor suppression by overexpressing accessory proteins that mediate post-translational modifications or otherwise block PP2A enzymatic activity (Hwang et al., 2016; Leulliot et al., 2004…”
Cited by
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
Chen, P.-H., Hu, Z., An, E., Okeke, I., Zheng, S., Luo, X., Gong, A., Jaime-Figueroa, S., & Crews, C. M. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00693 · Cited by 130
TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors
Liu, J., Yu, X., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04824 · Cited by 73
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Vit, G., Duro, J., Rajendraprasad, G., Hertz, E. P. T., Holland, L. K. K., Weisser, M. B., McEwan, B. C., Lopez‐Mendez, B., Sotelo‐Parrilla, P., Jeyaprakash, A. A., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2022110611 · Cited by 34
Metadata
- Authors
- Morita, K., He, S., Nowak, R. P., Wang, J., Zimmerman, M. W., Fu, C., Durbin, A. D., Martel, M. W., Prutsch, N., Gray, N. S., Fischer, E. S., & Look, A. T.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 181
- Issue
- 3
- Pages
- 702-715.e20
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3016671066
- Cited by
- 78
- References
- 11
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.